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Abstract
Cleavage of caldesmon with chymotrypsin yields a series of fragments which bind both calmodulin
and actin and inhibit the binding of myosin subfragments to actin and the subsequent stimulation of
ATPase activity. Several of these fragments have been purified by cation exchange chromatography
and their amino-terminal sequences determined. The smallest fragment has a molecular mass of about
7.3 kDa and extends from Leu597 to Phe665. This polypeptide inhibits the actin-activated ATPase of
myosin S-1; this inhibition is augmented by smooth muscle tropomyosin and relieved by Ca2+-
calmodulin. The binding of the 7.3-kDa fragment to actin is competitive with the binding of S - 1 to
actin. Thus, this polypeptide has several of the important features characteristic of intact caldesmon.
However, although an intact caldesmon molecule covers between six and nine actin monomers, the
7.3-kDa fragment binds to actin in a 1:1 complex. Comparison of this fragment with others suggests
that a small region of caldesmon is responsible for at least part of the interaction with both calmodulin
and actin.
Caldesmon is an actin- and calmodulin-binding protein isolated from smooth muscle (1) and
later shown to be a component of some nonmuscle cells (2–4). The role of caldesmon in these
cells has not been firmly established, but it does interact with several contractile proteins and
is a potent inhibitor of actin-activated ATP hydrolysis by myosin (5–8) and its subfragments
(9,10).
Structurally, caldesmon consists of two globular regions joined, in smooth muscle caldesmon,
by an elongated helical chain. The amino-terminal region of caldesmon binds to myosin (11,
12) forming a relatively strongly associated 1:1 complex in the presence of ATP (13). The
isolated myosin- binding segment does not affect ATP hydrolysis. The binding of caldesmon
to myosin is weakened both by phosphorylation of caldesmon (14,15) and by the binding of
Ca2+-calmodulin (12,15). Adjacent to the myosin binding region is an elongated helical
structure (16) which probably serves a structural function since it has no known activity and
is absent in the known nonmuscle caldesmon’s (17–19). The carboxyl-terminal region of
caldesmon was first isolated as a 40-kDa fragment from chymotryptic digests and was shown
to inhibit ATP hydrolysis in a Ca2+-calmodulin dependent manner (20–23). Further digestion
of the 40-kDa fragment yielded a product of about 20 kDa with properties similar to the 40-
kDa precursor (20,21,23). Both the 40-kDa (24) and the 20-kDa fragments (25) inhibit ATPase
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activity while lacking the ability of cross-linking myosin with actin. The 20-kDa fragments
also inhibit the binding of myosin S-1 to actin in the presence of ATP and can be displaced
from actin by rigor crossbridges.1 Furthermore, the 20-kDa fragments inhibit the attachment
of weakly binding cross-bridges in intact muscle fibers blocking force production (26).
In the present study we show that 20-kDa chymotryptic fragments of caldesmon originate at
either Lys579 or Leu597 and extend close to the carboxyl terminus of caldesmon. The population
of fragments beginning at Lys597 is similar, if not identical, to the 20-kDa fragment prepared
by Riseman et al. (23). We have shown that further digestion results in the production of a 7.3-
kDa fragment which begins at Leu597 and terminates at Phe665. This fragment binds to actin
with a stoichiometry of 1:1, inhibits ATPase activity, and binds to calmodulin. By comparison
with other known regions of caldesmon, these data further localize the location of major sites
of interaction with actin and calmodulin.
MATERIALS AND METHODS
Skeletal actin was isolated from rabbit back and leg muscles by a modification of the method
of Spudich and Watt (27,28). Smooth muscle tropomyosin was isolated from turkey gizzards
(29). Calmodulin was purified from porcine brains by the method of Yazawa et al. (30). Skeletal
muscle myosin was isolated from the back and leg muscles of rabbits (31), and chymotryptic
S-1 was prepared by the method of Weeds and Taylor (32). Smooth muscle myosin and S-1
were prepared from chicken gizzards (11). Caldesmon was isolated from turkey gizzards by a
modification of the method of Bretscher (29) described previously (33).
Protein concentrations were determined by absorbance at 280 nm except for caldesmon which
was determined by the Lowry assay using bovine serum albumin as a standard. The molecular
weights used for calculation of protein concentrations were S-1 (120,000), actin (42,000),
tropomyosin (68,000), calmodulin (16,500), and caldesmon (87,000). The average molecular
mass of the three actin-binding fragments of caldesmon c, d, and e was estimated to be 20 kDa
on the basis of mobility on SDS2 gels, size exclusion chromatography, and amino-terminal
amino acid sequence determination.
Caldesmon was cleaved with either a 1:500 or 1:1,000 mg ratio of chymotrypsin for 5 min at
25 °C in a buffer composed of 0.1 M KC1, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 1 mM
dithiothreitol. This procedure is similar to that used by Szpacenko and Dabrowska (21). To
purify the actin-binding fragments of caldesmon, the digest was applied to a 1.5 × 95-cm
column of Ultrogel AcA 54 (LKB) equilibrated with digestion buffer containing 1 M KCl. The
second and third peaks, containing the low molecular weight actin-binding fragments, were
pooled and applied to a 10-ml column of Affi-Gel Blue-Agarose (Bio-Rad) equilibrated with
digestion buffer. After washing the column, actin-binding fragments of caldesmon were eluted
with digestion buffer having a total KCl concentration of 0.5 M KCl. In some cases, the mixture
of actin-binding fragments was separated into individual components by cation exchange
HPLC using a Waters SP-R column. The column was equilibrated with 10 mM Tris-Mes (pH
7.0), 60 mM NaCl, 1 mM dithiothreitol, and the fragments were eluted with a NaCl gradient to
500 mM.
Binding Studies
The 7.3-kDa fragment of caldesmon was labeled with 125I using the Iodogen reagent (Pierce)
as described by the manufacturer. Labeling with [14C] iodoacetamide, the preferred method,
1L. Velaz and J. M. Chalovich, unpublished data.
2The abbreviations used are: SDS, sodium dodecyl sulfate; Mes, 4-morpholineethanesulfonic acid EGTA, [ethylenebis
(oxyethylenenitrilo)] tetraacetic acid.
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was impossible since this fragment lacked Cys. The binding of 125I-labeled caldesmon to actin
was determined by the depletion of radioactivity from the supernatant following sedimentation
of the reaction mixture at 160,000× g for 25 min in a 50-Ti rotor. The binding buffer contained
42 mM NaCl, 4.2 MgC12, 10 mM imidazole (pH 7.0), 0.25 mM EGTA, 1 mM dithiothreitol, 0.3
μM skeletal S-1, and 2 mM ATP. The binding data were corrected for 1) the fraction of caldesmon
which did not form a sediment even at saturating actin concentrations; 2) the amount of
caldesmon which was present in the sediment in the absence of actin; and (3) the fraction of
actin (5%) which did not form a sediment.
ATPase Assays
The ATPase activity of myosin skeletal S-1 was measured by the liberation of 32Pi from [32P]
ATP as described earlier (34).
Affinity Chromatography
Calmodulin was cross-linked to CNBr- activated Sepharose 4B according to the manufacture’s
protocol (Pharmacia LKB Biotechnology Inc.) as described earlier (25).
Electrophoresis and Autoradiography
Sodium dodecyl sulfate gels, with a 7–20% gradient of polyacrylamide, were run by the
procedure of Laemmli (35) and stained with Coomassie Blue.
Molecular Weight Estimation
An estimate of the molecular weight of the 20-kDa fragments of caldesmon was made on the
basis of retention time on a GF-250 (Du Pont) HPLC size exclusion column in a buffer
containing 0.3 M Na2HPO4 (pH 7.0). The calibration curve was linear with eight standards
having molecular weights between 94,000 and 12,400 (Sigma). Molecular weights of the 7.3-
and 20-kDa fragments were also estimated from mobility on calibrated SDS gels.
Primary Structure Determination
For the determination of amino acid composition fragments were further purified by reversed
phase HPLC on a μBondapak (Waters) C18 column equilibrated with 0.1% trifluoroacetic acid,
4.75% acetonitrile and eluted with a gradient of acetonitrile to 95%. Fractions containing the
polypeptide of interest were dried under N2 and hydrolyzed for amino acid analysis by the
Pico-Tag method (Waters). The amino-terminal sequence of the peptides was determined
following electrophoretic transfer from an SDS gel to an Immobilon (Millipore) polyvinylidene
difluoride membrane in a LKB semi-dry transphore apparatus. The solvent was composed of
39 mM glycine, 48 mM Tris, 0.0373% (w/v) SDS, and 20% methanol. The transfer was run for
15 min at 50 mA, 15 min at 100 mA, 15 min at 150 mA, and finally 45 min at 190 mA. Following
extensive washing with water and staining with Coomassie Blue, the bands of interest were
excised and placed directly into the sequenator. Analyses were usually terminated after 15–20
residues. The carboxyl- terminal sequence of the 7.3-kDa polypeptide was determined by
carboxypeptidase A (Worthington, 2 × crystallized) digestion at pH 8.5, 37 °C for 1 or 5 h.
The reaction was stopped by the addition of HCl to pH 2, and released amino acids were
determined.
RESULTS
Purification of Fragments and Localization in Caldesmon
Digestion of caldesmon with chymotrypsin has been shown earlier to produce a number of
fragments which bind to actin (20,21) and one which binds to myosin (25). Fig. 1 shows the
resolution of a chymotryptic digest of turkey gizzard caldesmon on cation exchange
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chromatography. This is a more extensive digestion than reported earlier (25). With the
exception of the first peak, all fractions inhibited the actin activation of ATP hydrolysis by
skeletal S-1. Furthermore, most of the polypeptides with estimated molecular masses between
7 and 22 kDa were found to bind to actin in co-sedimentation assays. We had shown earlier
that the three fragments migrating with a molecular mass of about 20-kDa (equivalent to those
in fraction j) inhibited actin-activated ATP hydrolysis and binding of heavy meromyosin to
actin (25). Furthermore, these fragments inhibit the interaction of myosin-ATP with actin in
skinned muscle fibers (26). Because of the apparent importance of this region of caldesmon
we determined the amino-terminal sequence of the 20-kDa fragments to localize them within
caldesmon. We also isolated and characterized the lowest molecular weight polypeptide, ~7.3
kDa, in fraction h of Fig. 1. This polypeptide was of particular interest because it was the
smallest polypeptide found to bind tightly to actin.
Purification of the 20-kDa fragments was best achieved from a digestion done with a 1:600 or
1:1,000 ratio of chymotrypsin to caldesmon. The digest was first chromatographed on a gel
permeation column (see Fig. 3), and the fraction containing the 20-kDa fragments was resolved
by chromatography on an SP HPLC cation exchange column (Waters). Fig. 2 is the elution
profile of the fragments in the 20-kDa range. Four polypeptide fragments were identified in
the peaks labeled 1, 2, and 3; each bound to actin in co-sedimentation experiments as shown
in Fig. 2. Furthermore, each of these fractions inhibits the actin-activated ATPase activity of
myosin (data not shown). The polypeptide fragments from a gel similar to that shown in Fig.
2 were transferred to a polyvinylidene difluoride membrane, and the individual bands were
excised for sequence analysis. These four polypeptides are all derived from the same region
of the caldesmon molecule. Two of the fragments began at Lys579; the smaller fragment must
be truncated at the carboxyl-terminal end. The other two fragments originate at Leu597. The
amino-terminal residues are given in Table I. The most likely carboxyl-terminal residue of
these polypeptides was determined from estimates of their molecular weights. These results
are also listed in Table I.
The smaller 7.3-kDa fragment was purified from a 1:500 digest with chymotrypsin following
initial fractionation on the SP HPLC cation exchange column as described in Fig. 1. The peak
enriched in the 7.3-kDa fragment (peak h in Fig. 1) was further purified by gel filtration as
shown in Fig. 3. This two-step purification was usually sufficient to produce a single band of
protein on heavily loaded SDS gels as shown in Fig. 3. The 7.3-kDa peptide was
electrophoretically transferred to polyvinylidene difluoride membranes for sequence analysis
and was shown to originate at Leu597 (Table I).
The carboxyl-terminal amino acid was determined by carboxypeptidase A digestion. Digestion
at 37 °C for 1 h at a carboxypeptidase A to protein ratio of 1:220 yielded Phe (578 pmol) and
a Val (206 pmol), whereas digestion for 5 h at a ratio of 1:20 yielded almost equal amounts of
Phe and Val (594 and 685 pmol, respectively). Therefore, the carboxyl-terminal residues are
Val-Phe. In the caldesmon sequence, there is only one Phe, Phe665, within 10 kDa of Leu597;
the residue preceding Phe665 is Val664. This is the only Val-Phe sequence between Leu597 and
Pro756. The presence of Phe at the carboxyl terminus is also consistent with a fragment
produced by cleavage with chymotrypsin. Therefore, the fragment isolated extends from
Leu597 to Phe665 and has a molecular mass of 7309 daltons (Table I).
Estimates of the carboxyl termini of the other fragments were made on the basis of their
molecular weights determined on SDS- polyacrylamide gels. However, since intact caldesmon
and other fragments display aberrant mobility on SDS gels (37) this result was confirmed by
other methods. In the case of the actin-binding fragments, the molecular weights were also
estimated by the retention time on an HPLC gel permeation column. The molecular mass and
predicted location of all four fragments are given in Table I and Fig. 7. These data show that
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the 7.3-kDa fragment is derived from the 20-kDa fragments, and both are derived from the 35–
40- kDa fragment studied by others (20–23).
Interaction of the 7.3-kDa Fragment with Actin and Actin- Tropomyosin Filaments
The properties of the 7.3-kDa polypeptide were studied in more detail since this fragment binds
to actin and is a derivative of larger fragments known to be important for the function of
caldesmon. Fig. 4 shows the binding of highly purified 7.3-kDa fragment to actin and actin-
tropomyosin filaments. Most of the data were obtained using 125I-labeled peptide, but the three
highest points were obtained with unlabeled caldesmon using quantitative gel electrophoresis.
Binding saturated at a stoichiometry of 1.1 peptides/actin monomer with an association
constant of 4.9 × 104 M−1. There is no evidence of cooperativity in the binding. This binding is
1% as tight (Klω) as intact caldesmon (33) and 5–10% as tight as the binding of the 20-kDa
actin-binding fragments (Velaz et al., Biophys. J. 1991). Although relatively weak, the
interaction of the 7.3-kDa fragment is about 10- fold stronger than the binding of S-1-ATP to
actin under identical conditions. Unlike intact caldesmon (one per seven to ten actin monomers)
or the 20-kDa fragments (one per two actin monomers), the 7.3-kDa fragment binds to a single
actin monomer and must contain a key determinant for actin binding.
The binding of intact caldesmon to actin is known to be enhanced by tropomyosin (33,38).
However, there is little, if any, effect of smooth muscle tropomyosin on the binding of the 7.3-
kDa fragment to actin. The inset to Fig. 4 shows the low concentration region of the binding
curve in more detail. There is little difference between the binding in the presence (solid
circles) and absence (open circles) of tropomyosin. In support of this observation, we have
also observed a lack of tropomyosin effect on binding with the larger 20-kDa fragment.1
The binding of intact caldesmon to actin is inhibited by rigor S-1 binding (11) and by Ca2+-
calmodulin (33,38,39). The inset to Fig. 4 also shows that binding of the 7.3-kDa fragment is
inhibited by both skeletal S-1 and Ca2+-calmodulin. Using a simple competitive model the
reversal of caldesmon-actin binding by calmodulin behaves as if the association constant of
Ca2+-calmodulin to caldesmon is about 2 × 105 M−1. This is about 50% as tight as our estimate
for binding to intact caldesmon by the same method (33).
The 7.3-kDa Fragment Binds to Ca2+-Calmodulin
The ability of the 7.3-kDa fragment to bind directly to calmodulin was confirmed by affinity
chromatography. Fig. 5 shows that the 7.3-kDa fragment binds to a calmodulin-Sepharose
column in the presence of Ca2+ but is released when the free Ca2+ concentration is lowered by
the addition of EGTA. This observation supports an earlier suggestion (40) that the sequence
from TrP659 to Phe665 is essential and perhaps sufficient for binding to Ca2+-calmodulin.
Inhibition of the Actin-activated ATPase of Myosin
Another characteristic property of caldesmon is the ability to inhibit the activation of myosin
ATPase activity by actin. Fig. 6 demonstrates that the 7.3-kDa fragment of caldesmon inhibits
the actin-activated ATPase activity in a concentration-dependent manner. The concentration
of 7.3-kDa fragment required for inhibition is greater than for intact caldesmon in accord with
the difference in affinity. However, the degree of inhibition by the fragment (about 90%) is
similar to intact caldesmon. It is interesting that although tropomyosin has little effect on the
binding of the 7.3-kDa fragment to actin, tropomyosin does facilitate inhibition of ATPase
activity. Similar inhibition was observed on two additional preparations. Fig. 6 also shows that
the 7.3-kDa fragment inhibits ATPase activity of smooth muscle S-1. Note that the
effectiveness of this fragment for smooth and skeletal S-1 cannot be compared since different
fragment preparations were used. The inset to Fig. 6 shows that inhibition of ATPase activity
is reversed by Ca2+-calmodulin.
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DISCUSSION
Caldesmon has been shown to bind stoichiometrically to myosin (1:l in the presence of ATP)
(13), actin (one per six to nine actin monomers in a filament) (9,33,41–44), calmodulin (one
per two calmodulins) (40,45–47), and to tropomyosin (1:1) (48). The binding site for myosin
(14,25) as well as one calmodulin binding site are in the amino-terminal region of caldesmon
(45), whereas the actin binding site(s) and a second calmodulin binding site are located at the
carboxyl- terminal region (20–22,49,50). These two regions of caldesmon are separated, in
smooth muscle caldesmon, by a long helical region (16). It is unclear whether the carboxyl-
terminal actin binding domain alone positions the long flexible caldesmon molecule on F-actin
and may cooperatively regulate actomyosin or whether additional actin binding sites are
necessary. One approach to understanding the function of caldesmon is to define the location
of the various binding regions within the primary structure of caldesmon.
The actin binding site(s) of caldesmon is particularly interesting since binding to actin inhibits
activation of ATP hydrolysis and could be of regulatory importance. Several recent studies
have been directed toward defining the actin sequences involved in binding to caldesmon.
There is agreement that caldesmon binds near the amino-terminal 7 residues of actin (51–53),
a region that has been implicated in the binding of S-1-ATP (54,55). Caldesmon binding to
actin is also perturbed slightly by antibodies directed against a peptide containing amino acid
residues 18–28 of actin (51). This peptide may be involved in rigor myosin binding to actin
(63). Recently, the carboxyl-terminal region of actin has been shown to affect the interaction
with caldesmon (56–58), but this is probably an indirect effect resulting from the close
proximity of the carboxyl- and amino-terminal regions of actin. The 20- kDa fragments,
extending from Lys579 (or Leu597) through the end of the molecule, are competitive with
antibodies directed against the amino-terminal 7 residues of actin although the effect is not as
dramatic as with intact caldesmon (51). Thus, the 20-kDa fragment contains part, but perhaps
not all, of the actin binding site(s) of caldesmon.
We have defined the actin binding region of the 20-kDa fragment using more extensive
chymotryptic digestion to produce smaller actin-binding fragments. A peptide, derived from
the 20-kDa fragments, having an apparent molecular mass of about 7.3 kDa has been purified
extensively. The 7.3- kDa peptide begins at Leu597 and ends at Phe665. Fig. 7 summarizes the
location of the fragments of caldesmon generated in this study along with several fragments
produced in other laboratories. Solid bars indicate polypeptides with a demonstrated ability to
block the actin activation of myosin ATPase. Note that not all of the fragments have been tested
for inhibitory activity; an open bar does not necessarily imply a lack of inhibitory activity. The
20-kDa fragments originate either at Lys579 (a) or Leu597 (b). Both of these fragments have
heterogeneity in their carboxyl-terminal regions and may end either at Phe752 or near Thr740.
These different carboxyl-terminal ends are not indicated in Fig. 7. The 7.3-kDa fragment
derived from a and b and which contains their major activities is labeled k. All fragments which
are known to inhibit ATPase activity overlap to some degree with fragment k. Thus it is highly
likely that this region is important in the inhibition of ATP hydrolysis (it will be shown later
that other regions may also be important for ATPase inhibition).
Our observation that the 7.3-kDa fragment binds to calmodulin is consistent with data from
other laboratories. Fragment g (Wang’s fragment 15) binds to calmodulin, whereas fragment
h (Wang’s fragment 15′) does not (40). This restricts the calmodulin binding sequence to
residues 629–666. Comparison with fragment i (59) narrows the calmodulin binding region to
residues 659–666, which is almost completely within the 7.3-kDa region of caldesmon
(fragment k). Recently, a synthetic peptide including residues Gly651 through Ser667, of
caldesmon (Fig. 7, fragment p) was shown to bind to calmodulin and also weakly to actin
(60).
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It is also reasonable that our 7.3-kDa fragment binds to actin and inhibits actin-activated ATP
hydrolysis. Consider fragments l and m (19), n (61), and o (36,62). Each has been reported to
bind to actin to some degree, although only fragment l, which contains the entire 7.3-kDa
sequence of fragment k, inhibits ATP hydrolysis. Comparison of the 7.3- kDa fragment, k, with
fragments l and m (19) suggests that the peptide between 570 and 670 is critical for inhibition
for ATPase activity. Hayashi et al. (19) have restricted this region further by arguing, from a
comparison of fragments labeled d and l, that a smaller region, between 621 and 673, is
sufficient for both inhibition of ATPase activity and reversal by Ca2+- calmodulin.
Bartegi et al. (59) have reported that a CNBr fragment, i, inhibits ATPase activity and is
reversed by Ca2+ in a manner similar to the 7.3-kDa fragment (fragment k). These fragments
have only a 7-amino acid sequence overlap, between residues 659 and 665. It is unclear,
however, whether the properties of fragment i (59) and fragment k are functionally the same
since their reported stoichiometries of binding to actin are very different. The stoichiometry
of the 7.3-kDa fragment to actin is 1 mol of fragment to 1 mol of actin. In contrast, the
stoichiometry for fragment i reported by Bartegi et al. (59) is 1:7, more similar to intact
caldesmon than to any of the shorter fragments. We consider the value for fragment k to be
reasonable since we determined the stoichiometry of intact caldesmon to be between 1:7 and
1:10 and the 20-kDa fragment (fragment a) to be 1:2 using the same method. Furthermore,
others have measured stoichiometries of binding for the 38-kDa actin binding region to be
about 1:4 and that of the 20-kDa fragment (fragment a) to be about 1:2 (23). It is unclear how
the shorter fragment i could either acquire additional binding sites and/or be able to sterically
interfere with fragment binding to additional actin monomers. This issue needs to be resolved
since it is crucial to understanding whether caldesmon has a single actin binding site centered
around residues 659–665 or two sites flanking this peptide as suggested by Wang et al. (40).
The available data are consistent either with two binding sites, one on fragment k and a second
on fragment i or with a single site overlapping the small shared peptide.
It should be pointed out that Wang et al. observed that a deletion of the terminal 39 amino acid
residues from fragment a resulted in a fragment c which was a poor inhibitor of actin- activated
ATPase activity (40). They suggested that caldesmon binds to actin through residues 597–629
and at 711–756 and that the latter region, at the extreme carboxyl-terminal end of caldesmon,
is important for maintenance of ATPase activity. The former region (597–629) is thought to
have the higher actin affinity since fragments f and c (Wang’s fragments 19a and CaD 579–
717) bind to actin more tightly than fragment e (Wang’s fragment 19b) (40). Note that fragment
c (Wang’s CaD 579–717) was shown to inhibit ATPase activity. The involvement of the
carboxyl-terminal region in ATP-ase inhibition may be supported by the analysis of peptide
i by Bartegi et al. (59). However, as stated earlier, peptide i overlaps residues 659–665 of
peptide k, and it is possible that these residues, and not the extreme carboxyl-terminal region,
are critical for inhibition. Wang et al. also observed that neither peptide h (their peptide 15′)
(40) nor j (61) binds to actin, although both contain the carboxyl-terminal region of caldesmon.
While this could be taken as evidence that the carboxyl-terminal region is not critical, Wang
et al. suggested that the lack of binding by peptide h is because of the presence of a sequence
which blocks binding to actin. However, we also note that peptide h is missing the 659–665
sequence which we suggest is important for inhibition of ATPase activity. Lack of binding of
fragment j (61), equivalent to fragment i which does bind to actin (59), has been attributed to
the harsh isolation conditions (59). We have also prepared a carboxyl-terminal caldesmon
fragment using CNBr digestion (Table I). In our own preliminary experiments, this fragment
did bind to actin in agreement with Bartegi et al. (53). Wang et al. (40) have isolated an
additional fragment, g (their fragment 15), which has the peculiar property of binding
calmodulin but not actin, although it contains the 659–665 overlap peptide. The lack of actin
binding of this peptide has been attributed to an inhibitory sequence (40). The possibility of
an additional inhibitory site at the carboxyl terminus of caldesmon must be considered.
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Hayashi et al. (19) and Mornet et al. (36,62) have argued for an additional actin binding site
on fragments m, n, and o in the sequence between 446 and 578. These fragments do not inhibit
ATP hydrolysis, It is unclear whether all these putative actin binding sequences are in close
proximity with each other in space forming a single actin binding site or whether they are
separated and able to associate with different actin monomers. The presence of several actin
binding regions on caldesmon which interact with different actin monomers is an attractive
prospect since the stoichiometry of binding of caldesmon to actin varies with the size of the
caldesmon fragment. However, only two separate, nonoverlapping sets of peptides have been
shown to bind to actin, those containing sequence 446–578 and those containing sequence 659–
665. Alternatively, binding of the carboxyl-terminal region of caldesmon to actin may position
the rest of the caldesmon molecule so that the binding of additional caldesmon fragments is
sterically blocked from binding. The longer the polypeptide attached to the carboxyl-terminal
end, the greater is the apparent stoichiometry of binding. Determination of the region(s) of both
actin and caldesmon involved in binding should differentiate between these models.
Caldesmon is able to virtually eliminate the binding of S-1-ATP to actin (10), whereas
nucleotide-free S-1 is able to displace virtually all bound caldesmon from actin (11). There-
fore any proposal for the binding of caldesmon to actin must be able to explain the ability of
one caldesmon molecule to compete with about seven molecules of S-1. These competition
data have been successfully modeled by assuming that 1) caldesmon binds to one or two actin
monomers through the amino-terminal region of actin totally blocking the binding of S-1 to
these residues, and 2) the rest of the caldesmon molecule only partially inhibits the binding of
S-1 to actin3. Thus, the function of caldesmon does not require that it has a series of identical
binding sites. Rather, a single strong binding site, such as that described in this report, as well
as weaker interactions with other actin monomers (at undefined regions of the actin monomer)
are sufficient to explain available binding data.
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Fig. 1. HPLC cation exchange chromatography of a chymotryptic digest.
Caldesmon was digested with a 1:500 (w:w) ratio of chymotrypsin to caldesmon for 5 min at
25 °C. The digest was loaded onto a Waters SP R column equilibrated with 10 mM Tris- Mes
(pH 7.0), 60 mM NaCl, 1 mM dithiothreitol. The column was washed with 15 ml of the same
buffer followed by a gradient to 10 mM Tris-Mes, 500 mM NaCl, 1 mM dithiothreitol. Fraction
h is enriched in the 7.3-kDa fragment, and fractions i and j were used as the source of the 20-
kDa actin-binding fragments. The arrows denote the position of actin (42,000) and soybean
trypsin inhibitor (21,500) standards.
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Fig. 2. HPLC cation exchange purification of the 20-kDA fragments and demonstration of binding
to actin.
Crude 20-kDa fragments were first prepared by AcA 54 gel filtration of a 1:1,000
(chymotrypsin:caldesmon) digest of caldesmon. Fractions containing the 20-kDa fragments
were applied to a Waters SP R column as described in Fig. 1, and the elution pattern is shown
here. The peaks labeled 1,2, and 3 were enriched in the polypeptides of interest. Inset, the
contents of the three peaks were tested for actin binding in co-sedimentation assays; a
Coomassie Blue-stained electrophoretic transfer of an SDS gel of both supernatants and pellets
of peaks 1,2, and 3 is shown. The arrow shows the position of actin which is present only in
the pellets. Each peak is enriched in a single polypeptide which binds to actin. The bands were
subsequently excised from the blots shown and used for sequence analysis.
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Fig. 3. Purification of the 7.3-kDa fragment of caldesmon.
Fraction h from Fig. 1 was applied to a 1.5 × 90-cm column of AcA 54 equilibrated with 500
mM KCl, 20 mM Tris (pH 8), 1 mM EDTA, 1 mM EGTA, and 1 mM dithiothreitol and washed
with the same buffer at a flow rate of 15 ml/h. Traces of polypeptides greater than 35 kDa were
eluted at 88 ml (peak A). 20-kDa fragments were eluted at 105 ml (peak B). Pure 7.3-kDa
fragment was eluted at 134 ml (peak C), and peak D was unidentified. The inset shows the
pure 7.3- kDa fragment (C) and molecular weight standards (ST). The pure 7.3-kDa fragment
was subsequently transferred to a polyvinylidene difluoride membrane for amino-terminal
analysis.
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Fig. 4. Binding of the 7.3-kDa fragment of caldesmon to actin and actin-tropomyosin.
Either caldesmon or 125I-caldesmon was co-sedimented with 5 μM actin (○) or 5 μM actin with
1.4 μM smooth muscle tropomyosin (•) at 25 °C in a buffer containing 42 mM NaCl, 4.3 mM
MgCl2, 11 mM imidazole-HCl (pH 7.0), 0.25 mM EGTA, and 1 mM dithiothreitol. In experiments
with calmodulin, the EGTA was replaced with 0.5 mM CaCl2. The inset is an expanded view
of the data at low 7.3-kDa fragment concentration. Also included are data obtained in the
presence of 6 μM S-1 (+) or 20 μM calcium-calmodulin (×). All data were obtained with a single
preparation of the 7.3-kDA fragment.
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Fig. 5. Binding of the 7.3-kDa fragment to calmodulin-Sepharose.
0.25 mg of 7.3-kDa fragment of caldesmon in 150 mM NaCl, 10 mM imidazole-HCl (pH 7.0),
1 mM CaCl2, and 1 mM NaN3 was loaded onto a 1-ml column of calmodulin-Sepharose (10 mg
of calmodulin/ml of Sepharose) equilibrated with the same buffer. At the position indicated,
the buffer was replaced with a similar buffer with the CaCl2 replaced by 2 mM EGTA. The
column was run at 5 °C at a flow rate of 5 ml/h, and the absorbance was monitored at 280 nm.
Electrophoretic analysis confirmed the presence of the 7.3-kDa fragment in both the
breakthrough peak and the major peak.
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Fig. 6. Inhibition of the ATPase activity of acto-S-1 and reversal by calcium-calmodulin.
ATPase rates were measured at 25 °C in a buffer containing 1 mM ATP, 4.4 mM MgCl2, 10.4
mM imidazole-HCl (pH 7.0), 0.25 mM EGTA, and 1 mM dithiothreitol. The protein
concentrations were: 0.2 μM skeletal myosin S-1, and 10 μM actin without (○) or with (•) 2.8
μM smooth muscle tropomyosin. Also shown is the effect of a different preparation of the 7.3-
kDa fragment on smooth muscle S-1 in the absence of tropomyosin (×). Inset, reversal of
ATPase activity of skeletal S-1, in the presence of tropomyosin, with 10 and 20 μM total
calmodulin. For this experiment 0.25 mM CaCl2 was added rather than EGTA.
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Fig. 7. Summary of polypeptide fragments from the region of caldesmon extending from residue
450 through the carboxyl terminus (residue 756).
The primary structure derived from Bryan et al. (50) is used as a reference; residue numbers
from Hayashi et al. (19) have been reduced by 15 to compare with the other data shown. Solid
bars represent fragments with a demonstrated ability to inhibit actin-activated ATPase activity.
Upper case letters are used to indicate fragments which bind to actin A or calmodulin C.
Fragments a, b, and k are from the present paper. Fragments a and b were also discussed by
Velaz et al. (25), and fragment a was discussed by Hayashi et al. (19), and Riseman et al.
(23). Fragments c, e, f, g, and h are from Wang et al. (40); d, 1, and m are from Hayashi et
al. (19); fragment i is from Bartegi et al. (59); j and n are from Takagi et al. (61); o is from
Mornet et al. (36,62); and p is from Zhan et al. (60).
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Table I
Primary structure and molecular weight summary of chymotryptic fragments
Molecular mass estimates
SDS-PAGE Gel filtration Amino acid composition N terminus C terminus
kDa
22.9 22.9 Lys579 Pro756a
20.1 19.9 18.8 Lys579 Thr740-Phe752a
20.1 Lys597 Pro756a
18.2 15 14.9 Leu597 Thr740-Thr746a
10 7.8 Leu597 Phe665b
10c Tyr659-Ser666 Pro756a
a
Estimated from molecular weight.
b
 Determined from carboxypeptidase a digestion.
c
Prepared from a CNBr digestion of caldesmon.
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